Etheros
Etheros is developing a new class of small molecule drugs that mimic endogenous enzymes to prevent oxidative and inflammatory injury, particularly in neural tissue. Their lead compound has demonstrated neuroprotective effects in placebo-controlled animal studies and extends median lifespan in wild-type mice, offering transformative potential for neuroprotection and healthspan extension.
Founders
Dr Jack Scannell is best known for his work on R&D productivity where he coined the term “Eroom’s Law” ("Moore's law" backwards) to describe the contrast between the huge decline in R&D output efficiency since 1950 in the face of massive gains in the individual scientific activities on which drug discovery depends. His recent pre-Etheros work focused on the predictive power (or lack thereof) of disease models in drug discovery. Previously, he led Discovery Biology at e-Therapeutics PLC. He has experience in drug and biotech investment at UBS and at Sanford Bernstein where he ran the European Healthcare teams. He has a Ph.D. in neuroscience from Oxford and a degree in medical sciences from Cambridge.